Ads
related to: latest developments in schizophrenia and addiction recovery actconsumerhorse.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.
The bill was introduced by Senator Sheldon Whitehouse and Representative Jim Sensenbrenner as the first major federal addiction act in 40 years. [ 1 ] [ 2 ] CARA authorizes over $181 million to respond to the epidemic of opioid use disorder and is intended to greatly increase both prevention programs and the availability of treatment programs.
Mardepodect is currently one of the furthest advanced PDE 10A inhibitors in development and has progressed through to Phase II clinical trials in humans. [5] In 2017, development of mardepodect for the treatment of schizophrenia and Huntington's disease was discontinued.
Based on a recovery model, the common elements of the Soteria approach include the use of primarily nonmedical staff, who do not prescribe or administer antipsychotic medication to patients, and the preservation of residents' personal power, social networks, and communal responsibilities. [2]
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.
Ads
related to: latest developments in schizophrenia and addiction recovery actconsumerhorse.com has been visited by 100K+ users in the past month